Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
letrozole +/- goserelin (the latter for pre-menopausal women only) may fight breast cancer by
lowering the amount of estrogen the body makes. OSI-906 and erlotinib hydrochloride may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not
yet known whether hormone therapy and OSI-906 are more effective when given with or without
erlotinib hydrochloride in treating hormone-sensitive metastatic breast cancer.
PURPOSE: This phase II trial is studying how well giving hormone therapy together with
OSI-906 with or without erlotinib hydrochloride works in treating hormone-sensitive patients
with metastatic breast cancer.